Published in Am J Hum Genet on January 01, 1996
ER-associated degradation is required for vasopressin prohormone processing and systemic water homeostasis. J Clin Invest (2017) 1.44
A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest (2003) 1.00
Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. J Clin Invest (1997) 0.95
Misfolding of Mutated Vasopressin Causes ER-Retention and Activation of ER-Stress Markers in Neuro-2a Cells. Open Neuroendocrinol J (2011) 0.78
Two novel mutations in seven Czech and Slovak kindreds with familial neurohypophyseal diabetes insipidus-benefit of genetic testing. Eur J Pediatr (2016) 0.77
Structural Requirements for Sorting Pro-Vasopressin to the Regulated Secretory Pathway in a Neuronal Cell Line. Open Neuroendocrinol J (2008) 0.77
Utility of genetic testing in suspected familial cranial diabetes insipidus. Endocrinol Diabetes Metab Case Rep (2013) 0.75
Persistent severe polyuria after renal transplant. Clin Kidney J (2015) 0.75
Contributions of the interdomain loop, amino terminus, and subunit interface to the ligand-facilitated dimerization of neurophysin: crystal structures and mutation studies of bovine neurophysin-I. Protein Sci (2007) 0.75
Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a mutation in the arginine-vasopressin II gene in four generations of a Korean family. Ann Pediatr Endocrinol Metab (2014) 0.75
How signal sequences maintain cleavage specificity. J Mol Biol (1984) 11.03
DnaJ-like proteins: molecular chaperones and specific regulators of Hsp70. Trends Biochem Sci (1994) 3.65
Heat-shock proteins as molecular chaperones. Eur J Biochem (1994) 3.26
The endoplasmic reticulum as a protein-folding compartment. Trends Cell Biol (1992) 2.64
Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest (1973) 2.64
Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature (1982) 2.54
SEC11 is required for signal peptide processing and yeast cell growth. J Cell Biol (1988) 2.08
A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A (1994) 1.91
Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum. J Cell Biol (1992) 1.90
The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. J Biol Chem (1985) 1.73
Sorting and processing of secretory proteins. Biochem J (1994) 1.65
Specific diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in dried blood spots by a polymerase chain reaction (PCR) assay detecting a point-mutation (G985) in the MCAD gene. Clin Chim Acta (1991) 1.63
Signal peptidases in prokaryotes and eukaryotes--a new protease family. Trends Biochem Sci (1992) 1.57
The modification and assembly of proteins in the endoplasmic reticulum. Curr Opin Cell Biol (1993) 1.44
Dominant inheritance of diabetes insipidus; a family study. Pediatrics (1953) 1.40
Protein folding and the regulation of signaling pathways. Cell (1994) 1.39
Hereditary diabetes insipidus: report of 20 cases in seven generations. J Clin Endocrinol Metab (1955) 1.28
Maturation of Escherichia coli maltose-binding protein by signal peptidase I in vivo. Sequence requirements for efficient processing and demonstration of an alternate cleavage site. J Biol Chem (1990) 1.26
Crystal structure of a bovine neurophysin II dipeptide complex at 2.8 A determined from the single-wavelength anomalous scattering signal of an incorporated iodine atom. Proc Natl Acad Sci U S A (1991) 1.24
Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somat Cell Mol Genet (1985) 1.24
Familial diabetes insipidus. Q J Med (1959) 1.24
Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab (1993) 1.14
Glu-47, which forms a salt bridge between neurophysin-II and arginine vasopressin, is deleted in patients with familial central diabetes insipidus. J Clin Endocrinol Metab (1993) 1.09
HEREDITARY IDIOPATHIC DIABETES INSIPIDUS. A CASE REPORT WITH AUTOPSY FINDINGS. Ann Intern Med (1965) 1.09
Miscleavage at the presequence of rat preprolactin synthesized in pituitary cells incubated with a threonine analog. Cell (1981) 1.08
Heredtary and idiopathic types of diabetes insipidus. Brain (1967) 1.08
Familial cranial diabetes insipidus: a report of five families. Genetic, diagnostic and therapeutic aspects. Q J Med (1985) 1.08
Functional limits of conformation, hydrophobicity, and steric constraints in prokaryotic signal peptide cleavage regions. Wild type transport by a simple polymeric signal sequence. J Biol Chem (1991) 1.08
Substrate specificity of eukaryotic signal peptidase. Site-saturation mutagenesis at position -1 regulates cleavage between multiple sites in human pre (delta pro) apolipoprotein A-II. J Biol Chem (1988) 1.06
A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin Invest (1991) 1.00
Membrane topology and biogenesis of eukaryotic signal peptidase. J Biol Chem (1993) 0.94
Proteolysis in protein import and export: signal peptide processing in eu- and prokaryotes. Experientia (1992) 0.94
Radioimmunoassay of vasopressin in familial cental diabetes insipidus. J Pediatr (1982) 0.93
Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus. J Clin Invest (1993) 0.92
The distribution of physical, chemical and conformational properties in signal and nascent peptides. Biochem J (1990) 0.91
Inhibition by acidic phospholipids of protein degradation by ER-60 protease, a novel cysteine protease, of endoplasmic reticulum. FEBS Lett (1992) 0.91
Vasopressin function in familial cranial diabetes insipidus. Postgrad Med J (1981) 0.90
Structural features in the NH2-terminal region of a model eukaryotic signal peptide influence the site of its cleavage by signal peptidase. J Biol Chem (1990) 0.89
Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension. Eur J Clin Pharmacol (1984) 0.89
Two novel mutations in the coding region for neurophysin-II associated with familial central diabetes insipidus. J Clin Endocrinol Metab (1995) 0.89
A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal diabetes insipidus. EMBO J (1992) 0.87
The use of vasopressin assays in physiology and pathophysiology. Semin Nephrol (1994) 0.86
Changes in tissue sensitivity to vasopressin in hereditary hypothalamic diabetes insipidus. Klin Wochenschr (1981) 0.85
Expression of the vasopressin and oxytocin genes in human hypothalami. FEBS Lett (1985) 0.82
A de novo mutation in the coding sequence for neurophysin-II (Pro24-->Leu) is associated with onset and transmission of autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab (1994) 0.80
A family with congenital hypothalamic neurohypophyseal diabetes insipidus. Folia Med Neerl (1970) 0.79
Familial ADH-responsive diabetes insipidus: response to thiazides and chlorpropamide. Can Med Assoc J (1973) 0.79
Alterations in the cleavage site of the signal sequence for the secretion of human lysozyme by Saccharomyces cerevisiae. FEBS Lett (1988) 0.78
Characterization of a disease-causing Glu119-Lys mutation in the low-density lipoprotein receptor gene in two Danish families with heterozygous familial hypercholesterolemia. Hum Mutat (1994) 0.78
[Dominant heredity of diabetes insipidus caused by pitressin deficiency]. J Genet Hum (1955) 0.77
Familial central diabetes insipidus: vasopressin and nicotine stimulated neurophysin deficiency with subnormal oxytocin and estrogen stimulated neurophysin. Am J Med Sci (1983) 0.77
Plasma vasopressin in hereditary cranial diabetes insipidus. Acta Med Scand (1985) 0.76
Hereditary central diabetes insipidus: plasma levels of antidiuretic hormone in a family with a possible osmoreceptor defect. Can Med Assoc J (1984) 0.76
Crystal structure of the ternary complex of Phe-tRNAPhe, EF-Tu, and a GTP analog. Science (1995) 7.39
Calcium transients and intramembrane charge movement in skeletal muscle fibres. Nature (1979) 4.55
The crystal structure of elongation factor EF-Tu from Thermus aquaticus in the GTP conformation. Structure (1993) 3.20
The antidiuretic action of carbamazepine in man. Clin Sci Mol Med (1974) 3.17
Structural details of the binding of guanosine diphosphate to elongation factor Tu from E. coli as studied by X-ray crystallography. EMBO J (1985) 3.14
The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest (1973) 2.79
Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest (1973) 2.64
A model for the tertiary structure of p21, the product of the ras oncogene. Science (1985) 2.61
The crystal structure of Cys-tRNACys-EF-Tu-GDPNP reveals general and specific features in the ternary complex and in tRNA. Structure (1999) 2.49
Contractile activation by voltage clamp depolarization of cut skeletal muscle fibres. J Physiol (1978) 2.21
The osmoregulation of vasopressin. Kidney Int (1976) 2.19
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet (1999) 1.99
Bacterial polypeptide release factor RF2 is structurally distinct from eukaryotic eRF1. Mol Cell (2001) 1.86
Helix unwinding in the effector region of elongation factor EF-Tu-GDP. Structure (1996) 1.82
Structural basis for nucleotide exchange and competition with tRNA in the yeast elongation factor complex eEF1A:eEF1Balpha. Mol Cell (2000) 1.78
Refined structure of elongation factor EF-Tu from Escherichia coli. J Mol Biol (1992) 1.74
The GTP binding motif: variations on a theme. FASEB J (1996) 1.73
Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms. Mol Genet Metab (2008) 1.73
Effect of caffeine on intramembrane charge movement and calcium transients in cut skeletal muscle fibres of the frog. J Physiol (1983) 1.68
Oligonucleotide-priming methods for the chromosome-specific labelling of alpha satellite DNA in situ. Chromosoma (1989) 1.66
Neurogenic disorders of osmoregulation. Am J Med (1982) 1.65
Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest (1999) 1.64
Crystal structures of nucleotide exchange intermediates in the eEF1A-eEF1Balpha complex. Nat Struct Biol (2001) 1.62
Increased optical transparency associated with excitation--contraction coupling in voltage-clamped cut skeletal muscle fibres. Nature (1977) 1.61
Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol (1989) 1.52
The regulation of vasopressin function in health and disease. Recent Prog Horm Res (1976) 1.51
Plasma vasopressin response to hypertonic saline infusion to assess posterior pituitary function. J R Soc Med (1980) 1.50
Role of vasopressin in the impaired water excretion of glucocorticoid deficiency. Kidney Int (1980) 1.50
One short well conserved region of Alu-sequences is involved in human gene rearrangements and has homology with prokaryotic chi. Nucleic Acids Res (1995) 1.49
Ethylmalonic encephalopathy: clinical and biochemical observations. Neuropediatrics (2007) 1.49
Age related nocturnal urine volume and maximum voided volume in healthy children: reappraisal of International Children's Continence Society definitions. J Urol (2010) 1.47
Effect of laser acupuncture for monosymptomatic nocturnal enuresis on bladder reservoir function and nocturnal urine output. J Urol (2011) 1.47
Protein misfolding and degradation in genetic diseases. Hum Mutat (1999) 1.46
Detection of alpha 1-antitrypsin genotypes by analysis of amplified DNA sequences. Nucleic Acids Res (1988) 1.45
Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. J Clin Endocrinol Metab (1996) 1.44
Tyrosyl-tRNA synthetase forms a mononucleotide-binding fold. J Mol Biol (1982) 1.44
Immunoassay of plasma vasopressin in man. Proc Natl Acad Sci U S A (1970) 1.43
[Successful delivery following continuous cytostatic therapy of a leukemic pregnant women]. Orv Hetil (1993) 1.39
[Effect of ACE gene polymorphism on left ventricular function in patients with type 2 diabetes]. Vnitr Lek (2003) 1.39
[Effects of growth hormone replacement therapy in adults with severe growth hormone deficiency]. Orv Hetil (2000) 1.38
Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med (1988) 1.37
Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol (1996) 1.37
The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? Hum Mol Genet (1997) 1.36
Diurnal anti-diuretic-hormone levels in enuretics. J Urol (1985) 1.35
Abnormalities of sodium and H2O handling in chronic obstructive lung disease. Arch Intern Med (1982) 1.35
How perchlorate improves excitation-contraction coupling in skeletal muscle fibers. Biophys J (1983) 1.34
Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. J Gen Physiol (2001) 1.32
Solution structure of the ternary complex between aminoacyl-tRNA, elongation factor Tu, and guanosine triphosphate. Biochemistry (1998) 1.31
Influence of the emetic reflex on vasopressin release in man. Kidney Int (1979) 1.31
General (medium-chain) acyl-CoA dehydrogenase deficiency (non-ketotic dicarboxylic aciduria): quantitative urinary excretion pattern of 23 biologically significant organic acids in three cases. Clin Chim Acta (1983) 1.30
Frequency of the G985 MCAD mutation in the general population. Lancet (1991) 1.30
In vitro fibroblast studies in a patient with C6-C10-dicarboxylic aciduria: evidence for a defect in general acyl-CoA dehydrogenase. Clin Chim Acta (1982) 1.29
VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab (2006) 1.29
Intramembrane charge movement and sarcoplasmic calcium release in enzymatically isolated mammalian skeletal muscle fibres. J Physiol (1997) 1.28
Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci U S A (1990) 1.28
High resolution x-ray crystallographic analysis of a modified form of the elongation factor Tu: guanosine diphosphate complex. J Mol Biol (1978) 1.26
Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest (1976) 1.24
The ternary complex of aminoacylated tRNA and EF-Tu-GTP. Recognition of a bond and a fold. Biochimie (1996) 1.23
The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab (1976) 1.20
Structural features of the GDP binding site of elongation factor Tu from Escherichia coli as determined by x-ray diffraction. FEBS Lett (1981) 1.19
Proceedings: Cyclophosphamide and the kidney. Cancer (1974) 1.18
Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. Hum Mol Genet (1996) 1.17
Zinc-binding site of an S100 protein revealed. Two crystal structures of Ca2+-bound human psoriasin (S100A7) in the Zn2+-loaded and Zn2+-free states. Biochemistry (1999) 1.17
The influence of morphology on prognosis in acute leukemia. Can Med Assoc J (1967) 1.17
Studies on the effects of saturated and unsaturated short-chain monocarboxylic acids on the energy metabolism of rat liver mitochondria. Pediatr Res (1979) 1.17
Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol (2000) 1.17
Perchlorate and the relationship between charge movement and contractile activation in frog skeletal muscle fibres. J Physiol (1987) 1.17
Comparison of birefringence signals and calcium transients in voltage-clamped cut skeletal muscle fibres of the frog. J Physiol (1983) 1.16
A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med (1981) 1.16
Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun (2012) 1.16
Abnormalities of thirst regulation. Kidney Int (1984) 1.15
High resolution crystal structure of bovine mitochondrial EF-Tu in complex with GDP. J Mol Biol (2000) 1.15
Vitamin D insufficiency in Greenlanders on a westernized fare: ethnic differences in calcitropic hormones between Greenlanders and Danes. Calcif Tissue Int (2003) 1.14
The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int (2002) 1.14
The crystal structure of tyrosyl-transfer RNA synthetase at 2-7 A resolution. J Mol Biol (1976) 1.14
Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab (1993) 1.14
Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase. Pediatr Res (1996) 1.14
C6-C10-dicarboxylic aciduria: investigations of a patient with riboflavin responsive multiple acyl-CoA dehydrogenation defects. Pediatr Res (1982) 1.14
Contraction threshold and the "hump" component of charge movement in frog skeletal muscle. J Gen Physiol (1991) 1.13
Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol (1979) 1.13
Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr Res (2001) 1.13
Hypodipsic hypernatremia with normal osmoregulation of vasopressin. N Engl J Med (1986) 1.10
Macromolecular mimicry. EMBO J (2000) 1.10
Acyl-CoA-binding protein/diazepam-binding inhibitor gene and pseudogenes. A typical housekeeping gene family. J Mol Biol (1992) 1.09
Familial cranial diabetes insipidus: a report of five families. Genetic, diagnostic and therapeutic aspects. Q J Med (1985) 1.08
A comparison between conservative and operative treatment of acute acromioclavicular dislocation. Acta Orthop Scand (1974) 1.08
Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol (1996) 1.07
Mutations in the medium chain acyl-CoA dehydrogenase (MCAD) gene. Hum Mutat (1992) 1.07
Action potentials and potassium currents in rat ventricular muscle during experimental diabetes. J Mol Cell Cardiol (1992) 1.07
The ternary complex of EF-Tu and its role in protein biosynthesis. Curr Opin Struct Biol (1997) 1.06
Endothelin in renovascular and essential hypertension. Blood Press (1994) 1.06
Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes (1979) 1.06
The effects of angiotensin-converting enzyme inhibition on sodium handling in patients with advanced chronic obstructive pulmonary disease. Am Rev Respir Dis (1987) 1.06
The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol (1978) 1.06
Tumour-like thallium-201 accumulation in brain infarcts, an unexpected finding on single-photon emission tomography. Eur J Nucl Med (1994) 1.06